Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 12/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517111 | 1.00 | FKBP1A (0.47) | FKBP1AHSD17B10SMN1; SMN2ROCK2HPGD | |
| SCHEMBL540702 | 1.00 | FKBP1A (0.47) | FKBP1AHSD17B10SMN1; SMN2ROCK2HPGD | |
| SCHEMBL750515 | 0.95 | HSD17B10 (0.50) | FKBP1AHSD17B10SMN1; SMN2ROCK2LMNA | |
| SCHEMBL11932167 | 0.95 | HSD17B10 (0.50) | FKBP1AHSD17B10SMN1; SMN2ROCK2LMNA | |
| SCHEMBL27410636 | 0.89 | HSD17B10 (0.52) | FKBP1AHSD17B10SMN1; SMN2ROCK2LMNA | |
| SCHEMBL6234399 | 0.88 | HSD17B10 (0.39) | FKBP1AHSD17B10SMN1; SMN2ROCK2HPGD | |
| SCHEMBL927348 | 0.87 | HSD17B10 (0.56) | FKBP1AHSD17B10SMN1; SMN2HPGDLMNA | |
| SCHEMBL28153746 | 0.87 | HSD17B10 (0.56) | FKBP1AHSD17B10SMN1; SMN2HPGDLMNA | |
| SCHEMBL12529807 | 0.87 | FKBP1A (0.47) | FKBP1AHSD17B10ROCK2HPGDCASP3 | |
| SCHEMBL3880061 | 0.85 | FKBP1A (0.46) | FKBP1AHSD17B10ROCK2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | FKBP1A 2896/4885HSD17B10 1951/4885SMN1; SMN2 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.